FY2017 EPS Estimates for Ultragenyx Pharmaceutical Inc Increased by Wedbush (RARE)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) – Analysts at Wedbush upped their FY2017 earnings estimates for shares of Ultragenyx Pharmaceutical in a research report issued to clients and investors on Wednesday. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of ($7.48) for the year, up from their prior estimate of ($7.49). Wedbush also issued estimates for Ultragenyx Pharmaceutical’s Q4 2017 earnings at ($2.26) EPS, Q1 2018 earnings at $0.74 EPS, Q2 2018 earnings at ($2.04) EPS, Q3 2018 earnings at ($0.71) EPS, Q4 2018 earnings at ($2.06) EPS, FY2018 earnings at ($4.06) EPS, FY2019 earnings at ($7.69) EPS, FY2020 earnings at ($6.51) EPS, FY2021 earnings at ($2.76) EPS and FY2022 earnings at $0.70 EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.87). The firm had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.02 million. During the same period in the prior year, the business earned ($1.64) EPS. Ultragenyx Pharmaceutical’s quarterly revenue was up 81.8% on a year-over-year basis.

A number of other equities analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. JPMorgan Chase & Co. reissued a “buy” rating and set a $76.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Sunday, November 5th. Robert W. Baird lowered their target price on shares of Ultragenyx Pharmaceutical from $85.00 to $80.00 and set an “outperform” rating for the company in a research note on Friday, November 3rd. Cowen reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 15th. Finally, Jefferies Group raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and lifted their target price for the stock from $58.00 to $72.00 in a research note on Monday, December 4th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the stock. Ultragenyx Pharmaceutical currently has a consensus rating of “Hold” and an average price target of $72.06.

Ultragenyx Pharmaceutical (RARE) opened at $49.16 on Monday. Ultragenyx Pharmaceutical has a 52 week low of $43.14 and a 52 week high of $91.35. The firm has a market cap of $2,093.68, a price-to-earnings ratio of -7.05 and a beta of 1.83.

A number of institutional investors and hedge funds have recently bought and sold shares of RARE. Capital International Investors grew its holdings in shares of Ultragenyx Pharmaceutical by 21.9% during the third quarter. Capital International Investors now owns 2,895,481 shares of the biopharmaceutical company’s stock valued at $154,213,000 after buying an additional 520,496 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Ultragenyx Pharmaceutical by 10.4% during the second quarter. BlackRock Inc. now owns 3,497,591 shares of the biopharmaceutical company’s stock valued at $217,237,000 after buying an additional 330,911 shares during the last quarter. State Street Corp grew its holdings in shares of Ultragenyx Pharmaceutical by 21.4% during the second quarter. State Street Corp now owns 1,536,285 shares of the biopharmaceutical company’s stock valued at $95,417,000 after buying an additional 270,729 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Ultragenyx Pharmaceutical by 933.2% during the second quarter. Royal Bank of Canada now owns 224,261 shares of the biopharmaceutical company’s stock valued at $13,929,000 after buying an additional 202,556 shares during the last quarter. Finally, Pictet Asset Management Ltd. grew its holdings in shares of Ultragenyx Pharmaceutical by 27.4% during the third quarter. Pictet Asset Management Ltd. now owns 750,407 shares of the biopharmaceutical company’s stock valued at $39,967,000 after buying an additional 161,196 shares during the last quarter. 94.10% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “FY2017 EPS Estimates for Ultragenyx Pharmaceutical Inc Increased by Wedbush (RARE)” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/01/22/fy2017-eps-estimates-for-ultragenyx-pharmaceutical-inc-increased-by-wedbush-rare.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply